Stay updated with breaking news from Trima Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
EscharEx® Phase III study protocol:FDA/EMA-aligned; patient enrollment commencing early 2024; two key research collaborations with wound industry ...
EscharEx® Phase III study protocol: FDA/EMA-aligned; patient enrollment commencing early 2024; two key research collaborations with wound industry leaders NexoBrid® U.S. commercial launch timing not